Human papillomavirus and cervical cancer

Lancet

Volumn 370, Issue 9590, 2007, Pages 890-907

  Schiffman, Mark ^a   Castle, Philip E ^a   Jeronimo, Jose ^a   Rodriguez, Ana C ^a   Wacholder, Sholom ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INFECTION RISK; MALIGNANT TRANSFORMATION; PRECANCER; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM; VIRUS INFECTION; WART VIRUS;

EID: 34548497655     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61416-0     Document Type: Review

References (172)

1. Parkin D., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Parkin D., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24 suppl 3 (2006) S11-S25
3. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., and El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 6 (2005) 204
4. Munoz N., Castellsague X., de Gonzalez A., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24 suppl 3 (2006) S1-S10
5. Castle P., Schiffman M., Bratti M., et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 190 (2004) 458-467
6. Castle P., Jeronimo J., Schiffman M., et al. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res 66 (2006) 1218-1224
7. Jacobson D., Peralta L., Farmer M., Graham N., Wright T., and Zenilman J. Cervical ectopy and the transformation zone measured by computerized planimetry in adolescents. Int J Gynaecol Obstet 66 (1999) 7-17
8. Dobbs S., Asmussen T., Nunns D., Hollingworth J., Brown L., and Ireland D. Does histological incomplete excision of cervical intraepithelial neoplasia following large loop excision of transformation zone increase recurrence rates? A six year cytological follow up. BJOG 107 (2000) 1298-1301
9. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., and Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 99 (2005) S7-S11
10. Cox J., Schiffman M., and Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 188 (2003) 1406-1412
11. de Gonzalez A.B., and Green J. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8 097 women with squamous cell carcinoma and 1 374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 120 (2007) 885-891
12. Sherman M., Wang S., Carreon J., and Devesa S. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 103 (2005) 1258-1264
13. Bray F., Carstensen B., Moller H., et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 14 (2005) 2191-2199
14. Berrington de Gonzalez A., Sweetland S., and Green J. Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis. Br J Cancer 90 (2004) 1787-1791
15. Altekruse S., Lacey Jr. J., Brinton L., et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: northeastern United States. Am J Obstet Gynecol 188 (2003) 657-663
16. de Villiers E., Fauquet C., Broker T., Bernard H., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
17. Schiffman M., Herrero R., Desalle R., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337 (2005) 76-84
18. Smith J., Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 (2007) 621-632
19. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287 (2002) 2114-2119
20. Wells M., Ostor A., Crum C., et al. Epithelial tumours. In: Tavassoli F., and Devilee P. (Eds). Pathology and genetics of tumours of the breast and female genital organs. 1st edn. (2003), IARC, Lyon, France 259-290
21. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110 (2006) 525-541
22. Munger K., Basile J., Duensing S., et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20 (2001) 7888-7898
23. Mantovani F., and Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20 (2001) 7874-7887
24. Schiffman M., and Castle P. The promise of global cervical-cancer prevention. N Engl J Med 353 (2005) 2101-2104
25. Malpica A., Matisic J., Niekirk D., et al. Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologic issues. Gynecol Oncol 99 3 suppl 1 (2005) S38-S52
26. Stoler M., and Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285 (2001) 1500-1505
27. Burchell A., Winer R., de Sanjose S., and Franco E. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 24 suppl 3 (2006) S52-S61
28. Roberts J., Buck C., Thompson C., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13 (2007) 857-861
29. Mendez F., Munoz N., Posso H., et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 192 (2005) 1158-1165
30. Plummer M., Schiffman M., Castle P., Maucort-Boulch M., and Wheeler C. A 2-year prospective study of HPV persistence among women with ASCUS or LSIL cytology. J Infect Dis 195 (2007) 1582-1589
31. Herrero R., Castle P., Schiffman M., et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191 (2005) 1796-1807
32. Castellsague X., Bosch F., Munoz N., et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 346 (2002) 1105-1112
33. Winer R., Lee S., Hughes J., Adam D., Kiviat N., and Koutsky L. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218-226
34. Baseman J., and Koutsky L. The epidemiology of human papillomavirus infections. J Clin Virol 32 suppl 1 (2005) S16-S24
35. Pagliusi S., Dillner J., Pawlita M., Quint W., Wheeler C., and Ferguson M. Chapter 23: International standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine 24 suppl 3 (2006) S193-S200
36. Sherman M. Chapter 11: future directions in cervical pathology. J Natl Cancer Inst Monogr 31 (2003) 72-79
37. Davey D., Neal M., Wilbur D., Colgan T., Styer P., and Mody D. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 128 (2004) 1224-1229
38. Moscicki A., Shiboski S., Hills N., et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364 (2004) 1678-1683
39. Kinney W., Manos M., Hurley L., and Ransley J. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 91 (1998) 973-976
40. Kovacic M., Castle P., Herrero R., et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 66 (2006) 10112-10119
41. Kurman R., Schiffman M., Lancaster W., et al. Analysis of individual human papillomavirus types in cervical neoplasia: a possible role for type 18 in rapid progression. Am J Obstet Gynecol 159 (1988) 293-296
42. Woodman C., Collins S., Rollason T., et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 361 (2003) 40-103
43. Moscicki A., Hills N., Shiboski S., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285 (2001) 2995-3002
44. Castle P., Wacholder S., Sherman M., et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 95 (2002) 2145-2151
45. Kjaer S., Hogdall E., Frederiksen K., et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66 (2006) 10630-10636
46. Khan M., Castle P., Lorincz A., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
47. Stanley M. Immune responses to human papillomavirus. Vaccine 24 suppl 1 (2006) S16-S22
48. Castle P., Schiffman M., Herrero R., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191 (2005) 1808-1816
49. Bulkmans N., Berkhof J., Bulk S., et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 96 (2007) 1419-1424
50. Schiffman M., and Kjaer S. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31 (2003) 14-19
51. Strickler H., Burk R., Fazzari M., et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 97 (2005) 577-586
52. Sawaya G., McConnell K., Kulasingam S., et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 349 (2003) 1501-1509
53. von Knebel D. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38 (2002) 2229-2242
54. Castle P., Stoler M., Solomon D., and Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 127 (2007) 805-815
55. Woodman C., Collins S., Winter H., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 (2001) 1831-1836
56. Richardson H., Kelsall G., Tellier P., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12 (2003) 485-490
57. Rodriguez A., Burk R., Herrero R., et al. The natural history of HPV infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis 34 (2007) 494-502
58. Kiviat N., Critchlow C., and Kurman R. Reassessment of the morphological continuum of cervical intraepithelial lesions: does it reflect different stages in the progression to cervical carcinoma?. IARC Sci Publ 119 (1992) 59-66
59. Castle P., Solomon D., Schiffman M., and Wheeler C. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97 (2005) 1066-1071
60. Lorincz A., Castle P., Sherman M., et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 360 (2002) 228-229
61. Ylitalo N., Sorensen P., Josefsson A., et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355 (2000) 2194-2198
62. Josefsson A., Magnusson P., Ylitalo N., et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355 (2000) 2189-2193
63. Sherman M., Wang S., Wheeler C., et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 12 (2003) 1038-1044
64. International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13 541 women with carcinoma of the cervix and 23 017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 118 (2006) 1481-1495
65. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16 563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 119 (2006) 1108-1124
66. Smith J., Green J., Berrington de Gonzalez A., et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361 (2003) 1159-1167
67. Smith J., Bosetti C., Munoz N., et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 111 (2004) 431-439
68. Garcia-Closas R., Castellsague X., Bosch X., and Gonzalez C. The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. Int J Cancer 117 (2005) 629-637
69. Khan M., Partridge E., Wang S., and Schiffman M. Socioeconomic status and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer 104 (2005) 61-70
70. Hogewoning C., Bleeker M., van den Brule A., et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 107 (2003) 811-816
71. Richardson H., Abrahamowicz M., Tellier P., et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 14 (2005) 1149-1156
72. Wang S., and Hildesheim A. Chapter 5: viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 31 (2003) 35-40
73. Carrington M., Wang S., Martin M., et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 201 (2005) 1069-1075
74. Palefsky J., Gillison M., and Strickler H. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 24 suppl 3 (2006) S140-S146
75. Harris T., Burk R., Palefsky J., et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 293 (2005) 1471-1476
76. Clifford G., Goncalves M., and Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20 (2006) 2337-2344
77. Gustafsson L., Ponten J., Zack M., and Adami H. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 8 (1997) 755-763
78. Peto J., Gilham C., Fletcher O., and Matthews F. The cervical cancer epidemic that screening has prevented in the UK. Lancet 364 (2004) 249-256
79. Chang A. Carcinoma in situ of the cervix and its malignant potential. A lesson from New Zealand. Cytopathology 1 (1990) 321-328
80. Kinlen L., and Spriggs A. Women with positive cervical smears but without surgical intervention. A follow-up study. Lancet 2 (1978) 463-465
81. Peitsaro P., Johansson B., and Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40 (2002) 886-891
82. Pirami L., Giache V., and Becciolini A. Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J Clin Pathol 50 (1997) 600-604
83. Arias-Pulido H., Peyton C., Joste N., Vargas H., and Wheeler C. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 44 (2006) 1755-1762
84. Wentzensen N., Vinokurova S., and von Knebel D. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 64 (2004) 3878-3884
85. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol (in press).
86. Schiffman M., Khan M., Solomon D., et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 97 (2005) 147-150
87. Shepherd J., Weston R., Peersman G., and Napuli I. Interventions for encouraging sexual lifestyles and behaviours intended to prevent cervical cancer. Cochrane Database Syst Rev 2 (2000) CD001035.
88. Winer R., Hughes J., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354 (2006) 2645-2654
89. Rose R., Bonnez W., Reichman R., and Garcea R. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 67 (1993) 1936-1944
90. Harro C., Pang Y., Roden R., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93 (2001) 284-292
91. Nardelli-Haefliger D., Wirthner D., Schiller J., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95 (2003) 1128-1137
92. Inglis S., Shaw A., and Koenig S. Chapter 11: HPV vaccines: commercial research & development. Vaccine 24 suppl 3 (2006) S99-S105
93. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
94. Garland S., Hernandez-Avila M., Wheeler C., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
95. Joura E., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (2007) 1693-1702
96. Villa L., Costa R., Petta C., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
97. Paavonen J., Jenkins D., Bosch F., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
98. Newall A., Beutels P., Wood J., Edmunds W., and MacIntyre C. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 7 (2007) 289-296
99. Saslow D., Castle P., Cox J., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57 (2007) 7-28
100. Markowitz L., Dunne E., Saraiya M., Lawson H., Chesson H., and Unger E. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 RR-2 (2007) 1-24
101. Viscidi R., Schiffman M., Hildesheim A., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13 (2004) 324-327
102. Wang S., Schiffman M., Shields T., et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 89 (2003) 1248-1254
103. Mao C., Koutsky L., Ault K., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 (2006) 18-27
104. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 viruslike particle vaccine among young women with preexisting infection. JAMA (in press).
105. Schiller J., and Nardelli-Haefliger D. Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine 24 suppl 3 (2006) S147-S153
106. Gambhira R., Gravitt P., Bossis I., Stern P., Viscidi R., and Roden R. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 66 (2006) 11120-11124
107. Wright Jr. T., and Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 348 (2003) 489-490
108. Solomon D., Breen N., and McNeel T. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin 57 (2007) 105-111
109. Anon. Cervix cancer screening (2005), IARC Press, IARC Handbooks of Cancer Prevention, Lyon
110. Gustafsson L., Ponten J., Bergstrom R., and Adami H. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 71 (1997) 159-165
111. Brinton LA, Schiffman M. Chapter 1. Epidemiology of gynecologic cancer. In: Barakat RR, Markman M, Randall ME, eds. Principles and practice of gynecologic oncology, 5th edn. Baltimore, MD: Lippincott Williams and Wilkins (in press).
112. Hildesheim A., Hadjimichael O., Schwartz P., et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 180 (1999) 571-577
113. Kitchener H., Castle P., and Cox J. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 24 suppl 3 (2006) S63-S70
114. Arbyn M., Sasieni P., Meijer C., Clavel C., Koliopoulos G., and Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 suppl 3 (2006) S78-S89
115. Davey E., d'Assuncao J., Irwig L., et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ 335 (2007) 31
116. Davey E., Barratt A., Irwig L., et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 367 (2006) 122-132
117. Ronco G., Segnan N., Giorgi-Rossi P., et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 98 (2006) 765-774
118. Fox R., Nix A., and Fielder H. A comparison of variability in Papanicolaou and liquid-based cytology inadequacy rates using Shewhart control charts. Cytopathology 17 (2006) 175-181
119. Ronco G., Cuzick J., Pierotti P., et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomised controlled trial. BMJ 335 (2007) 28
120. French D., Maissi E., and Marteau T. Psychological costs of inadequate cervical smear test results. Br J Cancer 91 (2004) 1887-1892
121. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., and Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96 (2004) 280-293
122. Kulasingam S., Kim J., Lawrence W., et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 98 (2006) 92-100
123. Cuzick J., Szarewski A., Cubie H., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 (2003) 1871-1876
124. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 7 (2006) 547-555
125. Walker J., Wang S., Schiffman M., and Solomon D. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol 195 (2006) 341-348
126. Kreimer A., Guido R., Solomon D., et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 15 (2006) 908-914
127. Carozzi F., Del Mistro A., Confortini M., et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol 124 (2005) 716-721
128. Wright Jr. T., Schiffman M., Solomon D., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 103 (2004) 304-309
129. Schiffman M., Wheeler C., Dasgupta A., Solomon D., and Castle P. A comparison of a prototype PCR assay and Hybrid Capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Pap smears. Am J Clin Pathol 124 (2005) 722-732
130. Van Doorn L., Quint W., Kleter B., et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 40 (2002) 979-983
131. Stoler M., Castle P., Solomon D., and Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 127 (2007) 1-3
132. Dunn S., Allen R., Wang S., Walker J., and Schiffman M. DNA extraction: an understudied and important aspect of HPV genotyping using PCR-based methods. J Virol Methods 143 (2007) 45-54
133. Clifford G., Franceschi S., Diaz M., Munoz N., and Villa L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 suppl 3 (2006) S26-S34
134. Clifford G., Gallus S., Herrero R., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (2005) 991-998
135. Gillison M., and Shah K. Chapter 9: role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 31 (2003) 57-65
136. Bulk S., Berkhof J., Bulkmans N., et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in the Netherlands. Br J Cancer 94 (2006) 171-175
137. Molden T., Kraus I., Karlsen F., Skomedal H., Nygard J., and Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4 136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14 (2005) 367-372
138. Wentzensen N., Hampl M., Herkert M., et al. Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. Cancer 107 (2006) 2307-2313
139. Wright Jr. T., Denny L., Kuhn L., Pollack A., and Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283 (2000) 81-86
140. Garcia F., Barker B., Santos C., et al. Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus. Obstet Gynecol 102 (2003) 266-272
141. Bais A., van Kemenade F., Berkhof J., et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 120 (2007) 1505-1510
142. Richart R., and Barron B. A follow-up study of patients with cervical dysplasia. Am J Obstet Gynecol 105 (1969) 386-393
143. Ferris D., and Litaker M. Prediction of cervical histologic results using an abbreviated Reid Colposcopic Index during ALTS. Am J Obstet Gynecol 194 (2006) 704-710
144. Jeronimo J., Massad L., Schiffman M., and for the National Institutes of Health/American Society of Colposcopy and Cervical Pathology (NIH/ASCCP) Research Group. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol 197 (2007) 47.e1-47.e8
145. Guido R., Schiffman M., Solomon D., and Burke L. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 188 (2003) 1401-1405
146. Pretorius R., Kim R., Belinson J., Elson P., and Qiao Y. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis 10 (2006) 5-9
147. Sherman M., Wang S., Tarone R., Rich L., and Schiffman M. Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias. Cancer Epidemiol Biomarkers Prev 12 (2003) 372-379
148. Gage J., Hanson V., Abbey K., et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 108 (2006) 264-272
149. Szarewski A., Jarvis M., Sasieni P., et al. Effect of smoking cessation on cervical lesion size. Lancet 347 (1996) 941-943
150. Prokopczyk B., Cox J., Hoffmann D., and Waggoner S. Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst 89 (1997) 868-873
151. Wright Jr. T., Cox J., Massad L., Carlson J., Twiggs L., and Wilkinson E. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol 189 (2003) 295-304
152. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., and Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367 (2006) 489-498
153. Cox J. Management of cervical intraepithelial neoplasia. Lancet 353 (1999) 857-859
154. Seamans Y., Sellors J., Broekhuizen F., and Howard M. Preliminary report of a gas conditioner to improve operational reliability of cryotherapy in developing countries. BMC Womens Health 6 (2006) 2
155. Santos C., Torres J., Sanchez J., Dasgupta A., and Jeronimo J. Lack of effectiveness of CO2 cryotherapy for treatment of CIN. Int J Gynaecol Obstet 87 (2004) 44-45
156. Schiffman M., and Adrianza M. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 44 (2000) 726-742
157. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., and Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 99 3 suppl 1 (2005) S7-S11
158. Dunne E., Unger E., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 297 (2007) 813-819
159. Kahn J., Slap G., Bernstein D., et al. Personal meaning of human papillomavirus and pap test results in adolescent and young adult women. Health Psychol 26 (2007) 192-200
160. Plante M., Renaud M., Hoskins I., and Roy M. Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 98 (2005) 3-10
161. Green J., Kirwan J., Tierney J., et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 3 (2005) CD002225.
162. Goldie S., Kim J., and Myers E. Chapter 19: cost-effectiveness of cervical cancer screening. Vaccine 24 suppl 3 (2006) S164-S170
163. Garnett G., Kim J., French K., and Goldie S. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 suppl 3 (2006) S178-S186
164. Franco E., Cuzick J., Hildesheim A., and de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 suppl 3 (2006) S171-S177
165. Goldie S., Gaffikin L., Goldhaber-Fiebert J., et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353 (2005) 2158-2168
166. Goldhaber-Fiebert J., and Goldie S. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc 4 (2006) 13
167. Denny L., Kuhn L., De Souza M., Pollack A., Dupree W., and Wright Jr. T. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 294 (2005) 2173-2181
168. Sankaranarayanan R., Nene B., Dinshaw K., et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 116 (2005) 617-623
169. Sangwa-Lugoma G., Mahmud S., Nasr S., et al. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer 119 (2006) 1389-1395
170. Sarian L., Derchain S., Naud P., et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study. J Med Screen 12 (2005) 142-149
171. Sankaranarayanan R., Esmy P., Rajkumar R., et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 370 (2007) 398-406
172. Cuzick J., Mayrand M., Ronco G., Snijders P., and Wardle J. Chapter 10: new dimensions in cervical cancer screening. Vaccine 24 suppl 3 (2006) S90-S97